No Data
No Data
Express News | Invivyd Elects Two New Independent Members to Its Board of Directors
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.
Invivyd Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 532.91% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/05/2024 279.75% Guggenheim → $9 Upgra
Strong Buy Rating for Invivyd Amidst Potential EUA Approval and Promising Revenue Projections
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia,
With 31% Stake, Invivyd, Inc. (NASDAQ:IVVD) Seems to Have Captured Institutional Investors' Interest